USPTO serial 88229098
KATRYZO
Reviewed by CopyMark Law Group
Status 605
- Filing date
- Status date
- Registration date
- —
- Examiner
- RISO, MARK E
- Law office
- GENERIC WEB UPDATE
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with KATRYZO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Pacific Palisades, CA
Pacific Palisades, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Chelsea E. Carbone
CHELSEA E. CARBONE WILSON SONSINI GOODRICH & ROSATI650 PAGE MILL ROADPALO ALTO, CA 94304-1050UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular disease, epilepsy and mitochondrial disease; vaccine preparations; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in in pediatric, geriatric, emergency, family, and human preventative medicine; Pharmaceutical preparations for the treatment of cancer, cardiovascular disease, epilepsy and mitochondrial disease | ABANDONED | — |
| 042 | Medical and pharmaceutical research services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, scientific research services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological services consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical, biopharmaceutical and chemical products; providing evaluation testing for pharmaceutical, biopharmaceutical and chemical products, and medical devices featuring testing for safety, toxicity, content, identity, purity, configuration and function for others, using chemical, in vitro or in vivo assays, analyses and models; pre-clinical and non-clinical evaluation testing of pharmaceutical, biopharmaceutical and chemical products performed primarily using animals and other biological models; pharmaceutical, biopharmaceutical, and chemical research and development for others; pharmaceutical research in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical research for use in pediatric, geriatric, emergency, family, and preventative medicine; pharmaceutical research for the treatment of infectious, deficiency, hereditary, and physiological diseases | ABANDONED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 2, 2019 | MAB5 | ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION | — |
| Jul 2, 2019 | ABN5 | ABANDONMENT - AFTER PUBLICATION | — |
| Jun 25, 2019 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| May 30, 2019 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| May 14, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 14, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 24, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 5, 2019 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Apr 5, 2019 | ALIE | ASSIGNED TO LIE | — |
| Mar 15, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 14, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 14, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 14, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 14, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 11, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 6, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 17, 2018 | NWAP | NEW APPLICATION ENTERED | — |